NEULANDLAB — Neuland Laboratories Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapFalling Star

Annual income statement for Neuland Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	9,369	9,511	11,912	15,586	14,768
Cost of Revenue
Gross Profit	4,049	4,238	5,856	8,573	7,263
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	8,273	8,556	9,609	11,552	12,191
Operating Profit	1,096	955	2,303	4,033	2,577
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,053	822	2,157	4,014	3,463
Provision for Income Taxes
Net Income After Taxes	806	638	1,635	3,001	2,601
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	806	638	1,635	3,001	2,601
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	806	638	1,635	3,001	2,601
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	63	50.8	128	248	158
Dividends per Share